Stock listing
BOATS:ABSI Absci Corporation Stock
US listing (BOATS) of Absci Corporation · home listing NASDAQ:ABSI
Follow Absci Corporation into a list and get an email when it puts out news.
Home listing price · NASDAQ:ABSI
$7.51 USD -0.67 (-8.2%)
Close on Nov 20, 2026 · This listing has no price on 6ix; the price shown is the home listing's, NASDAQ:ABSI
- Day range
- $7.45 – $8.14 USDNov 20, 2026
- Volume
- 4.74M sharesNov 20, 2026
- Market cap
- $1.30B USDAt the close on Nov 20, 2026 · price × 172.7M shares outstanding
- 52-week range
- $2.24 – $12.54 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- $38.24M USDMedian day 3.56M shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NASDAQ:ABSI · Home | $7.51 USD | -0.67 (-8.2%) | 4,744,482 | $7.91 | $8.14 | $7.45 | $8.18 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:ABSI · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $7.51 | -0.67 | -8.2% | $7.91 | $8.14 | $7.45 | 4,744,482 | |
| $8.18 | +0.60 | +7.9% | $7.60 | $8.73 | $7.60 | 5,664,227 | |
| $7.58 | +0.105 | +1.4% | $7.57 | $7.79 | $7.34 | 4,691,970 | |
| $7.475 | -0.975 | -11.5% | $8.15 | $8.15 | $7.29 | 7,867,474 | |
| $8.45 | -0.685 | -7.5% | $9.36 | $9.40 | $8.32 | 5,474,245 | |
| $9.135 | -0.985 | -9.7% | $9.47 | $9.94 | $8.96 | 4,910,926 | |
| $10.12 | +0.15 | +1.5% | $10.48 | $10.48 | $9.715 | 5,378,419 | |
| $9.97 | -0.83 | -7.7% | $10.44 | $10.91 | $9.675 | 4,102,369 | |
| $10.80 | +0.63 | +6.2% | $10.10 | $11.22 | $9.92 | 3,750,490 | |
| $10.17 | +0.78 | +8.3% | $9.83 | $10.26 | $9.51 | 4,149,657 | |
| $9.39 | -1.09 | -10.4% | $10.03 | $10.13 | $9.00 | 5,112,175 | |
| $10.48 | +0.48 | +4.8% | $10.26 | $10.68 | $9.78 | 4,151,767 | |
| $10.00 | +0.31 | +3.2% | $10.03 | $10.66 | $9.85 | 2,713,927 | |
| $9.69 | -1.44 | -12.9% | $11.29 | $11.32 | $9.68 | 3,787,828 | |
| $11.13 | -0.97 | -8.0% | $11.41 | $11.80 | $10.45 | 4,557,919 | |
| $12.10 | +0.22 | +1.9% | $11.91 | $12.54 | $11.91 | 4,303,126 | |
| $11.88 | +1.31 | +12.4% | $10.47 | $11.89 | $10.43 | 5,805,907 | |
| $10.57 | +1.12 | +11.9% | $9.61 | $10.95 | $9.36 | 5,814,853 | |
| $9.45 | +0.27 | +2.9% | $9.19 | $9.76 | $9.03 | 3,360,259 | |
| $9.18 | -0.19 | -2.0% | $9.28 | $9.35 | $8.965 | 1,888,993 | |
| $9.37 | -0.67 | -6.7% | $9.69 | $9.95 | $8.93 | 3,704,869 | |
| $10.04 | +0.97 | +10.7% | $9.24 | $10.20 | $9.114 | 5,346,252 | |
| $9.07 | +0.53 | +6.2% | $8.50 | $9.10 | $8.22 | 2,788,843 | |
| $8.54 | +0.29 | +3.5% | $8.69 | $8.96 | $8.395 | 2,757,646 | |
| $8.25 | -0.63 | -7.1% | $8.93 | $8.95 | $8.12 | 3,551,075 | |
| $8.88 | +0.14 | +1.6% | $8.43 | $8.945 | $8.23 | 3,395,649 | |
| $8.74 | -0.36 | -4.0% | $8.88 | $9.12 | $8.62 | 3,557,567 | |
| $9.10 | -0.57 | -5.9% | $9.445 | $9.66 | $9.00 | 3,042,600 | |
| $9.67 | -0.49 | -4.8% | $10.07 | $10.09 | $9.43 | 2,860,500 | |
| $10.16 | +1.22 | +13.6% | $9.20 | $10.39 | $8.93 | 4,241,800 | |
| $8.94 | -0.28 | -3.0% | $9.04 | $9.27 | $8.81 | 4,681,700 | |
| $9.22 | -1.05 | -10.2% | $10.00 | $10.22 | $9.12 | 5,850,900 | |
| $10.27 | -1.26 | -10.9% | $11.77 | $11.89 | $10.21 | 5,876,200 | |
| $11.53 | +0.46 | +4.2% | $11.11 | $11.80 | $10.87 | 4,294,900 | |
| $11.07 | +0.32 | +3.0% | $11.14 | $11.35 | $10.83 | 3,380,300 | |
| $10.75 | -0.02 | -0.2% | $10.80 | $11.27 | $10.55 | 4,605,100 | |
| $10.77 | +0.63 | +6.2% | $10.36 | $10.99 | $10.04 | 5,428,100 | |
| $10.14 | +0.65 | +6.8% | $9.59 | $10.18 | $9.485 | 3,423,500 | |
| $9.49 | -0.25 | -2.6% | $9.57 | $9.669 | $9.25 | 3,251,500 | |
| $9.74 | -0.605 | -5.8% | $10.49 | $10.50 | $9.68 | 3,206,600 | |
| $10.35 | +0.60 | +6.2% | $9.55 | $10.39 | $9.30 | 3,385,300 | |
| $9.745 | -0.965 | -9.0% | $10.51 | $10.62 | $9.47 | 4,715,100 | |
| $10.71 | +0.89 | +9.1% | $10.00 | $11.26 | $9.75 | 8,360,900 | |
| $9.82 | +0.17 | +1.8% | $10.06 | $10.15 | $9.50 | 4,556,400 | |
| $9.65 | +0.38 | +4.1% | $9.27 | $9.74 | $9.08 | 7,729,600 | |
| $9.27 | +1.23 | +15.3% | $8.295 | $9.83 | $8.285 | 8,659,400 | |
| $8.04 | +0.10 | +1.3% | $8.02 | $8.20 | $7.865 | 2,613,200 | |
| $7.94 | -0.15 | -1.9% | $8.055 | $8.07 | $7.79 | 2,341,800 | |
| $8.09 | -0.12 | -1.5% | $8.03 | $8.25 | $8.02 | 2,999,800 | |
| $8.21 | -0.03 | -0.4% | $8.42 | $8.57 | $8.11 | 1,965,800 | |
| $8.24 | -0.41 | -4.7% | $8.375 | $8.56 | $8.02 | 3,084,800 | |
| $8.65 | -0.26 | -2.9% | $8.89 | $9.02 | $8.625 | 2,030,300 | |
| $8.91 | +0.09 | +1.0% | $8.82 | $9.10 | $8.57 | 2,506,600 | |
| $8.82 | +0.02 | +0.2% | $8.69 | $9.03 | $8.65 | 2,150,200 | |
| $8.80 | 0.00 | 0.0% | $8.91 | $8.995 | $8.55 | 2,746,300 | |
| $8.80 | -0.04 | -0.5% | $8.90 | $9.23 | $8.36 | 2,946,900 | |
| $8.84 | -0.20 | -2.2% | $8.85 | $9.08 | $8.711 | 3,235,100 | |
| $9.04 | +0.33 | +3.8% | $8.67 | $9.09 | $8.62 | 5,257,200 | |
| $8.71 | -0.71 | -7.5% | $9.202 | $9.30 | $8.60 | 2,506,100 | |
| $9.42 | +0.20 | +2.2% | $9.28 | $9.679 | $9.155 | 3,210,200 | |
| $9.22 | -0.41 | -4.3% | $9.555 | $9.65 | $8.90 | 2,674,100 | |
| $9.63 | +0.79 | +8.9% | $9.11 | $9.705 | $9.10 | 2,339,877 | |
| $8.84 | -0.71 | -7.4% | $9.33 | $9.36 | $8.75 | 2,203,547 | |
| $9.55 | +0.27 | +2.9% | $9.56 | $9.90 | $9.50 | 2,331,000 | |
| $9.28 | -0.71 | -7.1% | $9.74 | $10.03 | $9.24 | 2,909,300 |
- Ticker
- BOATS:ABSI
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- BOATS
- Currency
- USD
What changed lately
Latest news release · Nov 12, 2026
Absci Reports Business Updates and Third Quarter 2026 Financial and Operating Results
Latest earnings call · Nov 12, 2026
Absci (NASDAQ:ABSI) Q3 2026 Earnings Call
Replay and transcript
Latest deck · Nov 12, 2026
Investor Presentation (November 2026)
Investor deck · 61 slides
Latest news
Absci Reports Business Updates and Third Quarter 2026 Financial and Operating Results
Nov 12, 2026
Closed $9.14 (-9.7%) on Nov 12, 2026
Absci Appoints Gerry Muhle as Chief Commercial Officer to Build Category-Defining Brands for ABS-201 and Its Broader Pipeline
Nov 12, 2026
Closed $9.14 (-9.7%) on Nov 12, 2026
Absci to Participate in Upcoming Investor Conferences
Oct 27, 2026
Closed $10.57 (+11.9%) on Oct 27, 2026
Absci to Report Business Updates and Third Quarter 2026 Financial and Operating Results on November 12, 2026
Oct 13, 2026
Closed $9.10 (-5.9%) on Oct 13, 2026
Absci to Report Business Updates and Second Quarter 2026 Financial and Operating Results on August 11, 2026
Jul 14, 2026
Closed $9.76 (-4.6%) on Jul 15, 2026
Absci Announces Pricing of $100 Million Underwritten Offering with Leading Strategic and Financial Investors
Jun 24, 2026
Closed $10.08 (+36.0%) on Jun 24, 2026
Absci Reports Business Updates and First Quarter 2026 Financial and Operating Results
May 7, 2026
Closed $5.90 (+2.6%) on May 8, 2026
Absci to Report Business Updates and First Quarter 2026 Financial and Operating Results on May 7, 2026
Apr 23, 2026
Closed $3.94 (-0.8%) on Apr 24, 2026
Absci to Participate in the 25th Annual Needham Virtual Healthcare Conference
Apr 8, 2026
Closed $2.99 (+2.4%) on Apr 8, 2026
Absci Reports Business Updates and Fourth Quarter and Full Year 2025 Financial and Operating Results
Mar 24, 2026
Closed $3.01 (+2.7%) on Mar 24, 2026
Absci Corporation on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 17 in the last 12 months · 124 in all · newest Nov 12, 2026 · oldest 2021
- Calls
- 12 calls with a replay · 12 with a transcript · latest Nov 12, 2026
- Decks
- 16 decks · latest Nov 12, 2026
Where Absci Corporation is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NASDAQ:ABSI · Home listing | NASDAQ | United States | USD |
| BOATS:ABSI · This page | BOATS | United States | USD |
Valuation
EV/sales 758× against a median of 21.3×: 8th lowest of 9 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026
- Enterprise value
- $1.13B USD
- P/E
- Loss
- EV/sales
- 758×
- EV/EBITDA
- Negative EBITDA
- Price/book
- 5.9×
- Gross margin
- Revenue too small
- Operating margin
- Revenue too small
- Net margin
- Revenue too small
- Debt to equity
- 0.0×
- Beta vs S&P 500
- 3.20
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Absci Corporation · NASDAQ:ABSI | US$1.30B | US$1.13B | n/a | 758× | n/a | 5.9× | n/a | 0.0× | 3.20 |
| Immunocore Holdings plc · NASDAQ:IMCR | US$1.36B | US$463.6M | n/a | 1.1× | n/a | 3.3× | −7.5% | 0.0× | 0.62 |
| Nanobiotix SA · EURONEXT:NANO | US$1.36B | US$1.36B | n/a | 41.7× | n/a | n/a | −80.8% | n/a | n/a |
| uniQure N.V. · NASDAQ:QURE | US$1.36B | US$739.1M | n/a | 36.6× | n/a | 4.6× | n/a | 0.2× | 1.25 |
| UroGen Pharma Ltd. · NASDAQ:URGN | US$1.36B | US$1.46B | n/a | 5.8× | n/a | n/a | −26.3% | n/a | 1.23 |
| OliX Pharmaceuticals, Inc. · KRX:226950 | US$1.31B | US$1.16B | n/a | 114× | n/a | 7.4× | −102.9% | 0.1× | n/a |
| Avalyn Pharma Inc. · NASDAQ:AVLN | US$1.26B | US$946.4M | n/a | n/a | n/a | 3.4× | n/a | 0.0× | 0.12 |
| LB Pharmaceuticals Inc · NASDAQ:LBRX | US$1.26B | US$858.7M | n/a | n/a | n/a | 3.0× | n/a | 0.0× | 0.81 |
| MannKind Corporation · NASDAQ:MNKD | US$1.24B | US$1.46B | n/a | 3.5× | 309× | n/a | −18.1% | n/a | 1.06 |
| Novavax, Inc. · NASDAQ:NVAX | US$1.23B | US$902.3M | n/a | 2.2× | n/a | n/a | −18.6% | n/a | 1.98 |
| Silence Therapeutics PLC · NASDAQ:SLN | US$1.23B | US$984.6M | n/a | 2,159× | n/a | 5.7× | n/a | 0.0× | 1.07 |
| Median of the others | US$1.28B | US$965.5M | 21.3× | 309× | 4.0× | −22.4% | 0.0× | 1.07 |
Forecasts
9 strong buy · 2 buy · 1 hold · Analysts' consensus from EODHD, read Nov 14, 2026. Not 6ix's view and not investment advice.
- Price target
- 14.73 USD · Analysts' mean
- EPS, year to Dec 2026
- -0.78 · 2 analysts
- Revenue, year to Dec 2026
- 3.72M · 11 analysts
Team and board
Officers
| Officer | Role |
|---|---|
| Sean McClain | Founder, CEO & Director |
| Zach Jonasson | Chief Financial Officer & Chief Business Officer |
| Mary Szela | President, TriSalus Life Sciences |
| Shelby Walker | Chief Legal Officer |
| Alex KhanVP | Finance & Investor Relations |
| Alexander Khan | CVP, Finance & Investor Relations |
| ContactAlex KhanVP | Finance & Investor Relations |
| Christine Lemke | SVP, Portfolio and Growth Strategy |
| Daniel Rabinovitsj | Vice President, Meta |
| Douglas Ganini da Silva | VP, Biologics Discovery & Research |
| Jeanne Schreuder | SVP, People & Experience |
| Michael Mangone | VP, Business Development |
| Moetaz Albizem | SVP, Clinical Operations |
| Todd Bedrick | SVP, Chief Accounting Officer |
| Gerry Muhle | Chief Commercial Officer |
| Ransi Somaratne | Chief Medical Officer |
| Wen Sha | Chief of Staff |
Board
| Director | Role |
|---|---|
| Sean McClain | Founder, CEO & Director |
Events
Calls
| Call | When | Status |
|---|---|---|
| Absci (NASDAQ:ABSI) Q3 2026 Earnings Call | Thu, Nov 12, 2026 · 8:00 AM ET | Replay |
| Absci (NASDAQ:ABSI) Q2 2026 Earnings Call | Tue, Aug 11, 2026 · 4:30 PM ET | Replay |
| Absci (NASDAQ:ABSI) Q1 2026 Earnings Call | Thu, May 07, 2026 · 4:30 PM ET | Replay |
| Absci (NASDAQ:ABSI) Q4 2025 Earnings Call | Tue, Mar 24, 2026 · 4:30 PM ET | Replay |
| Absci (NASDAQ:ABSI) Q3 2025 Earnings Call | Wed, Nov 12, 2025 · 4:30 PM ET | Replay |
| Absci (NASDAQ:ABSI) Q2 2025 Earnings Call | Tue, Aug 12, 2025 · 4:30 PM ET | Replay |
| Absci (NASDAQ:ABSI) Q1 2025 Earnings Call | Tue, May 13, 2025 · 4:30 PM ET | Replay |
| Absci (NASDAQ:ABSI) Q4 2024 Earnings Call | Tue, Mar 18, 2025 · 4:30 PM ET | Replay |
| Absci (NASDAQ:ABSI) Q3 2024 Earnings Call | Tue, Nov 12, 2024 · 8:00 AM ET | Replay |
| Absci (NASDAQ:ABSI) Q2 2024 Earnings Call | Wed, Aug 14, 2024 · 4:30 PM ET | Replay |
All 12 calls
| Call | When | Status |
|---|---|---|
| Absci (NASDAQ:ABSI) Q1 2024 Earnings Call | Tue, May 14, 2024 · 8:00 AM ET | Replay |
| Absci (NASDAQ:ABSI) Q3 2021 Earnings Call | Tue, Nov 09, 2021 · 8:30 AM ET | Replay |
Results days
| Quarter | Results | Share move |
|---|---|---|
| Q3 2026 | Nov 12, 2026 · Before open | −9.7% |
| Q2 2026 | Aug 11, 2026 · After close | +1.0% |
| Q1 2026 | May 7, 2026 · After close | +2.6% |
| Q4 2025 | Mar 24, 2026 | −0.3% |
| Q3 2025 | Nov 12, 2025 · After close | −22.4% |
| Q2 2025 | Aug 12, 2025 · After close | +5.0% |
| Q1 2025 | May 13, 2025 · After close | −1.7% |
| Q4 2024 | Mar 19, 2025 · Before open | −3.3% |
| Q3 2024 | Nov 12, 2024 · Before open | −14.9% |
| Q2 2024 | Aug 14, 2024 · After close | +11.0% |
All 20 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q1 2024 | May 14, 2024 · Before open | −4.5% |
| Q4 2023 | Mar 21, 2024 · Before open | +3.7% |
| Q3 2023 | Nov 14, 2023 · After close | 0.0% |
| Q2 2023 | Aug 14, 2023 · Before open | +5.4% |
| Q1 2023 | May 15, 2023 · After close | −8.6% |
| Q4 2022 | Mar 30, 2023 · After close | +4.2% |
| Q3 2022 | Nov 9, 2022 · Before open | +3.3% |
| Q2 2022 | Aug 11, 2022 · Before open | +14.1% |
| Q1 2022 | May 11, 2022 · Before open | −12.8% |
| Q4 2021 | Mar 22, 2022 · After close | +0.7% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Investor Presentation (November 2026) | Investor deck | 61 slides | Nov 12, 2026 |
| Investor Presentation (September 2026) | Investor deck | 60 slides | September 2026 |
| Investor Presentation (May 2026) | Investor deck | 58 slides | May 7, 2026 |
| Investor Presentation (March 2026) | Investor deck | 79 slides | Mar 24, 2026 |
| Jefferies Healthcare Conference (2026) | Conference | 23 slides | 2026 |
| 2026 J.P. Morgan Healthcare Conference | Conference | 23 slides | January 2026 |
| Goldman Sachs 47th Annual Global Healthcare Conference (2026) | Conference | 24 slides | 2026 |
| Investor Presentation (November 2025) | Investor deck | 84 slides | Nov 12, 2025 |
| Investor Presentation (August 2025) | Investor deck | 74 slides | Aug 12, 2025 |
| Corporate Update (May 2025) | Corporate update | 41 slides | May 13, 2025 |
All 16 decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Investor Presentation (March 2025) | Investor deck | 67 slides | Mar 18, 2025 |
| 2025 J.P. Morgan Healthcare Conference | Conference | 24 slides | Jan 15, 2025 |
| Technical Presentation (2025) | Technical | 35 slides | 2025 |
| Investor Presentation (November 2024) | Investor deck | 49 slides | Nov 12, 2024 |
| Investor Presentation (August 2024) | Investor deck | 49 slides | Aug 14, 2024 |
| 42nd J.P. Morgan Healthcare Conference (January 2024) | Conference | 22 slides | January 2024 |
Financings
| Raise | Date |
|---|---|
| Public offering of common stock Announced: about US$100M · US$7.41 a share · Jefferies +3 Dealers: Jefferies (co-lead), J.P. Morgan (co-lead), TD Cowen (co-lead), Guggenheim Securities (co-lead) Buyers: Eli Lilly & Company; Adage; BVF Partners; Columbia Threadneedle; Invus; Redmile Use of proceeds: Advance ABS-201 anti-PRLR antibody in androgenetic alopecia and endometriosis, plus working capital and general corporate purposes | Jun 24, 2026 |
| Public offering of common stock Announced: US$50M · US$3 a share · Morgan Stanley +4 Dealers: Morgan Stanley (co-lead), J.P. Morgan (co-lead), Jefferies (co-lead), TD Cowen (co-lead), TD Securities (USA) LLC (co-lead) Use of proceeds: Advancing internally developed programs, investment in its Integrated Drug Creation platform, working capital and general corporate purposes | Jul 24, 2025 |
| Strategic investment of equity (PIPE) Announced: US$20M Buyers: AMD ($20 million investment) | Jan 8, 2025 |
Open Financings · Read by 6ix AI from the company's releases
IPO
Priced at US$16.00 a share on Jul 21, 2021.
- Price
- US$16.00 a share
- Shares offered
- 12,500,000 shares of common stock
- Offering size
- US$200 million
- Underwriters' option
- Up to 1,875,000 more shares
- Listing
- ABSI on the Nasdaq Global Market
- Underwriters
- J.P. Morgan, Credit Suisse, BofA Securities, Cowen, Stifel · In the order on the cover
- Shares delivered
- On or about Jul 26, 2021
Steps
| Step | When |
|---|---|
| Draft sent to the SEC in confidence | May 6, 2021 |
| Filed publicly | Jun 30, 2021 |
| Amended 4 times | Newest Jul 20, 2021 |
| Shares registered with an exchange | Jul 21, 2021 |
| Declared effective by the SEC | Jul 21, 2021 |
| Final prospectus, with the price | Jul 23, 2021 |
Filings
| Filing | Filed |
|---|---|
| 424B4 · Prospectus | Jul 23, 2021 |
| EFFECT · Notice that a registration is effective | Jul 21, 2021 |
| CERT · Exchange's certificate of listing | Jul 21, 2021 |
| 8-A12B · Registration of shares for listing on an exchange | Jul 21, 2021 |
| CORRESP · Letter to the SEC | Jul 20, 2021 |
| S-1/A · Registration statement, amended | Jul 20, 2021 |
| UPLOAD · Letter from the SEC | Jul 20, 2021 |
| CORRESP · Letter to the SEC | Jul 19, 2021 |
| CORRESP · Letter to the SEC | Jul 19, 2021 |
| S-1/A · Registration statement, amended | Jul 19, 2021 |
All 22 filings
| Filing | Filed |
|---|---|
| CORRESP · Letter to the SEC | Jul 19, 2021 |
| CORRESP · Letter to the SEC | Jul 15, 2021 |
| S-1/A · Registration statement, amended | Jul 15, 2021 |
| UPLOAD · Letter from the SEC | Jul 14, 2021 |
| CORRESP · Letter to the SEC | Jul 8, 2021 |
| S-1/A · Registration statement, amended | Jul 8, 2021 |
| UPLOAD · Letter from the SEC | Jul 2, 2021 |
| S-1 · Registration statement | Jun 30, 2021 |
| DRS/A · Draft registration statement, amended | Jun 16, 2021 |
| DRSLTR · Letter to the SEC with a draft | Jun 15, 2021 |
| UPLOAD · Letter from the SEC | Jun 4, 2021 |
| DRS · Draft registration statement | May 6, 2021 |
Open IPO · From the cover of the final prospectus (424B4) filed Jul 23, 2021
Financials
Annual, in USD
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Revenue | 2.80M | 4.53M | 5.72M | 5.75M | 4.78M | 4.78M | 2.06M |
| Cost of revenue | 11.7M | 62.5M | 47.6M | 58.9M | 44.6M | 11.4M | 4.31M |
| Gross profit | -8.94M | -57.9M | -41.8M | -53.2M | -39.8M | -6.67M | 2.06M |
| Research and development | 81.4M | 63.9M | 48.1M | 58.9M | 44.6M | 11.4M | 4.31M |
| Selling, general and administrative | 35.1M | 36.2M | 37.8M | 40.6M | 28.8M | 5.50M | 3.52M |
| Operating income | -120.3M | -108.9M | -115.5M | -106.8M | -75.2M | -13.3M | -6.26M |
| Depreciation and amortization | 11.7M | 13.4M | 14.0M | 13.0M | 6.65M | 1.13M | 491.0K |
| EBITDA | -108.6M | -95.5M | -101.5M | -93.7M | -68.6M | -12.2M | -5.77M |
| Interest expense | 209.0K | 565.0K | 1.01M | 972.0K | 3.43M | 634.0K | 268.0K |
| Income before tax | -115.1M | -103.0M | -110.5M | -105.4M | -109.9M | -14.4M | -6.58M |
| Income tax | 69.0K | 70.0K | 100.0K | -461.0K | -8.90M | 0 | 217.0K |
| Net income | -115.2M | -103.1M | -110.6M | -104.9M | -101.0M | -14.4M | -6.58M |
| Earnings per share, basic | -0.84 | -0.94 | -1.20 | -1.15 | -2.08 | -3.19 | -0.07 |
| Earnings per share, diluted | -0.84 | -0.94 | -1.20 | -1.15 | -2.08 | -3.19 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Cash and equivalents | 20.0M | 41.2M | 72.4M | 60.0M | 252.6M | 69.9M | 13.1M |
| Short-term investments | 124.3M | 71.2M | 25.3M | 104.5M | 0 | ||
| Receivables | 0 | 2.19M | 1.55M | 1.43M | 1.59M | 222.0K | |
| Inventory | 15.0M | 10.5M | 1 | 1 | |||
| Current assets | 149.6M | 133.8M | 120.6M | 186.9M | 273.1M | 73.2M | 13.6M |
| Property, plant and equipment | 58.0M | 58.7M | 13.4M | 5.01M | |||
| Goodwill | 0 | 21.3M | 21.3M | 0 | |||
| Total assets | 216.3M | 213.6M | 217.3M | 321.0M | 426.2M | 88.6M | 19.5M |
| Accounts payable | 2.76M | 2.95M | 1.50M | 2.41M | 8.38M | 2.12M | 268.0K |
| Current liabilities | 22.8M | 28.7M | 29.6M | 30.3M | 33.9M | 10.1M | 3.47M |
| Long-term debt | 1.26M | 4.66M | 7.98M | 1.12M | 4.14M | 1.75M | |
| Total debt | 5.30M | 3.99M | 7.92M | 10.9M | 3.52M | 14.5M | 6.02M |
| Total liabilities | 26.8M | 34.5M | 41.1M | 46.6M | 60.1M | 21.6M | 60.6M |
| Shareholders' equity | 189.4M | 179.1M | 176.2M | 274.4M | 366.1M | -89.4M | -41.2M |
| Shares outstanding | 172.7M | 115.4M | 93.1M | 92.4M | 92.6M | 17.9M | 92.3M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Cash from operations | -92.9M | -72.4M | -64.6M | -81.3M | -60.6M | -11.0M | -6.03M |
| Capital spending | -1.11M | -404.0K | -860.0K | -16.2M | -38.0M | -2.18M | -1.10M |
| Free cash flow | -94.0M | -72.8M | -65.5M | -97.5M | -98.6M | -13.2M | -7.13M |
| Cash from investing | -50.2M | -41.6M | 81.9M | -127.0M | -67.4M | -2.17M | -1.09M |
| Cash from financing | 105.9M | 82.5M | -4.48M | 5.24M | 336.2M | 71.0M | 12.7M |
| Share buybacks | 210.4M | ||||||
| Change in cash | -37.1M | -31.5M | 12.8M | -203.1M | 208.2M | 57.8M | 5.58M |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 13, 2026 | Big-stake notice | SEC |
| S-3ASR · Registration statement | Nov 12, 2026 | Offer document | SEC |
| 10-Q · Quarterly report | Nov 12, 2026 | Quarterly report | SEC |
| 8-K · Current report | Nov 12, 2026 | Results | SEC |
| 4 · Change in ownership | Oct 30, 2026 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Oct 27, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Oct 14, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Oct 14, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Oct 14, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Sep 1, 2026 | Insider trade | SEC |
Show 200 filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 10-Q · Quarterly report | Aug 11, 2026 | Quarterly report | SEC |
| 8-K · Current report | Aug 11, 2026 | Results | SEC |
| 4 · Change in ownership | Aug 7, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Aug 7, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jul 6, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 26, 2026 | Insider trade | SEC |
| 8-K · Current report | Jun 24, 2026 | Material contract | SEC |
| 424B5 · Prospectus | Jun 24, 2026 | Offer document | SEC |
| 8-K · Current report | Jun 24, 2026 | Current report | SEC |
| 4/A · Change in ownership, amended | Jun 15, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 11, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 8, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 8, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 8, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 8, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 8, 2026 | Insider trade | SEC |
| 8-K · Current report | Jun 5, 2026 | Meeting outcome | SEC |
| 4 · Change in ownership | Jun 1, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 13, 2026 | Insider trade | SEC |
| 10-Q · Quarterly report | May 7, 2026 | Quarterly report | SEC |
| 8-K · Current report | May 7, 2026 | Results | SEC |
| ARS · Annual report to shareholders | Apr 22, 2026 | Annual report | SEC |
| DEFA14A · Additional proxy material | Apr 22, 2026 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 22, 2026 | Meeting notice | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Apr 14, 2026 | Big-stake notice | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Mar 26, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Mar 26, 2026 | Big-stake notice | SEC |
| S-8 · Registration statement for employee plans | Mar 24, 2026 | Offer document | SEC |
| 10-K · Annual report | Mar 24, 2026 | Annual report | SEC |
| 8-K · Current report | Mar 24, 2026 | Results | SEC |
| 4/A · Change in ownership, amended | Mar 16, 2026 | Insider trade | SEC |
| 4/A · Change in ownership, amended | Mar 16, 2026 | Insider trade | SEC |
| 4/A · Change in ownership, amended | Mar 16, 2026 | Insider trade | SEC |
| 4/A · Change in ownership, amended | Mar 16, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 16, 2026 | Insider trade | SEC |
| 8-K · Current report | Mar 6, 2026 | Material contract | SEC |
| 4 · Change in ownership | Mar 5, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 4, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 4, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 4, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 4, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 4, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 3, 2026 | Insider trade | SEC |
| 4/A · Change in ownership, amended | Mar 3, 2026 | Insider trade | SEC |
| 4/A · Change in ownership, amended | Mar 3, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 3, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 25, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 4, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 4, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 4, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 4, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 30, 2026 | Insider trade | SEC |
| SCHEDULE 13G · Big-stake notice | Jan 30, 2026 | Big-stake notice | SEC |
| 8-K · Current report | Jan 14, 2026 | Current report | SEC |
| 4 · Change in ownership | Dec 9, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 1, 2025 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 13, 2025 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Nov 12, 2025 | Quarterly report | SEC |
| 8-K · Current report | Nov 12, 2025 | Results | SEC |
| 8-K · Current report | Nov 4, 2025 | Material contract | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Oct 30, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Oct 14, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Oct 14, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Oct 14, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Oct 14, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Sep 24, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Sep 24, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Sep 2, 2025 | Insider trade | SEC |
| EFFECT · Notice that a registration is effective | Aug 25, 2025 | Other filings | SEC |
| 424B3 · Prospectus | Aug 22, 2025 | Offer document | SEC |
| CORRESP · Letter to the SEC | Aug 20, 2025 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Aug 19, 2025 | Other filings | SEC |
| 8-K/A · Current report, amended | Aug 12, 2025 | Results | SEC |
| S-3 · Registration statement | Aug 12, 2025 | Offer document | SEC |
| 10-Q · Quarterly report | Aug 12, 2025 | Quarterly report | SEC |
| 8-K · Current report | Aug 12, 2025 | Results | SEC |
| SCHEDULE 13G · Big-stake notice | Jul 29, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Jul 29, 2025 | Insider trade | SEC |
| 424B5 · Prospectus | Jul 25, 2025 | Offer document | SEC |
| 8-K · Current report | Jul 25, 2025 | Material contract | SEC |
| 424B5 · Prospectus | Jul 24, 2025 | Offer document | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Jul 16, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Jul 9, 2025 | Insider trade | SEC |
| 3 · Initial statement of ownership | Jul 9, 2025 | Insider trade | SEC |
| 8-K · Current report | Jul 8, 2025 | Management or board change | SEC |
| 4 · Change in ownership | Jun 12, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 12, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 12, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 12, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 12, 2025 | Insider trade | SEC |
| 8-K · Current report | Jun 12, 2025 | Meeting outcome | SEC |
| 4 · Change in ownership | Jun 2, 2025 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 15, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 15, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 14, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 14, 2025 | Big-stake notice | SEC |
| 10-Q · Quarterly report | May 13, 2025 | Quarterly report | SEC |
| 8-K · Current report | May 13, 2025 | Results | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 12, 2025 | Big-stake notice | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Apr 29, 2025 | Big-stake notice | SEC |
| ARS · Annual report to shareholders | Apr 28, 2025 | Annual report | SEC |
| DEFA14A · Additional proxy material | Apr 28, 2025 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 28, 2025 | Meeting notice | SEC |
| 8-K · Current report | Apr 28, 2025 | Management or board change | SEC |
| 424B3 · Prospectus | Apr 11, 2025 | Offer document | SEC |
| EFFECT · Notice that a registration is effective | Apr 11, 2025 | Other filings | SEC |
| CORRESP · Letter to the SEC | Apr 8, 2025 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Apr 7, 2025 | Other filings | SEC |
| S-3 · Registration statement | Apr 1, 2025 | Offer document | SEC |
| S-8 · Registration statement for employee plans | Mar 18, 2025 | Offer document | SEC |
| 10-K · Annual report | Mar 18, 2025 | Annual report | SEC |
| 8-K · Current report | Mar 18, 2025 | Results | SEC |
| 4 · Change in ownership | Mar 4, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 4, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 4, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 4, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 4, 2025 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 19, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 14, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 14, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Feb 4, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 4, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 4, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 4, 2025 | Insider trade | SEC |
| 8-K · Current report | Jan 15, 2025 | Current report | SEC |
| SCHEDULE 13G · Big-stake notice | Jan 10, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Dec 9, 2024 | Insider trade | SEC |
| SC 13G · Big-stake notice | Nov 14, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Nov 12, 2024 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Nov 12, 2024 | Quarterly report | SEC |
| 8-K · Current report | Nov 12, 2024 | Results | SEC |
| SC 13G · Big-stake notice | Nov 8, 2024 | Big-stake notice | SEC |
| SC 13G · Big-stake notice | Oct 18, 2024 | Big-stake notice | SEC |
| 4 · Change in ownership | Oct 16, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Oct 16, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Oct 16, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Oct 16, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Sep 4, 2024 | Insider trade | SEC |
| 8-K · Current report | Sep 4, 2024 | Current report | SEC |
| 10-Q · Quarterly report | Aug 14, 2024 | Quarterly report | SEC |
| 8-K · Current report | Aug 14, 2024 | Results | SEC |
| 4 · Change in ownership | Jul 3, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Jul 3, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 14, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 14, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 14, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 14, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 14, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 14, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 14, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 14, 2024 | Insider trade | SEC |
| 8-K · Current report | Jun 14, 2024 | Meeting outcome | SEC |
| 144 · Notice of proposed sale | Jun 13, 2024 | Other filings | SEC |
| 4 · Change in ownership | May 28, 2024 | Insider trade | SEC |
| 10-Q · Quarterly report | May 14, 2024 | Quarterly report | SEC |
| 8-K · Current report | May 14, 2024 | Results | SEC |
| ARS · Annual report to shareholders | Apr 23, 2024 | Annual report | SEC |
| DEFA14A · Additional proxy material | Apr 23, 2024 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 23, 2024 | Meeting notice | SEC |
| 4 · Change in ownership | Mar 21, 2024 | Insider trade | SEC |
| S-8 · Registration statement for employee plans | Mar 21, 2024 | Offer document | SEC |
| 10-K · Annual report | Mar 21, 2024 | Annual report | SEC |
| 8-K · Current report | Mar 21, 2024 | Results | SEC |
| 4 · Change in ownership | Mar 5, 2024 | Insider trade | SEC |
| SC 13D/A · Big-stake notice, amended | Mar 5, 2024 | Big-stake notice | SEC |
| 8-K · Current report | Feb 28, 2024 | Material contract | SEC |
| 424B5 · Prospectus | Feb 28, 2024 | Offer document | SEC |
| 8-K · Current report | Feb 27, 2024 | Results | SEC |
| 424B5 · Prospectus | Feb 27, 2024 | Offer document | SEC |
| SC 13G/A · Big-stake notice, amended | Feb 14, 2024 | Big-stake notice | SEC |
| 5 · Annual statement of ownership | Feb 14, 2024 | Insider trade | SEC |
| SC 13G · Big-stake notice | Feb 13, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Feb 9, 2024 | Big-stake notice | SEC |
| 4 · Change in ownership | Feb 5, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Feb 5, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Feb 5, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Feb 5, 2024 | Insider trade | SEC |
| 8-K · Current report | Jan 8, 2024 | Current report | SEC |
| 4 · Change in ownership | Jan 4, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Jan 4, 2024 | Insider trade | SEC |
| 8-K · Current report | Dec 20, 2023 | Current report | SEC |
| 8-K · Current report | Dec 7, 2023 | Management or board change | SEC |
| 8-K · Current report | Dec 4, 2023 | Current report | SEC |
| 10-Q · Quarterly report | Nov 14, 2023 | Quarterly report | SEC |
| 8-K · Current report | Nov 14, 2023 | Results | SEC |
| 4 · Change in ownership | Oct 16, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Oct 16, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Oct 16, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Oct 16, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Sep 6, 2023 | Insider trade | SEC |
This page holds 200 of 364 filings. Open Filings
Cap table
Built by 6ix from Absci Corporation’s releases · as of Oct 30, 2026
- Common shares
- 172,745,810
- Fully diluted
- 172,745,810
Fully diluted
| Line | Shares | As of |
|---|---|---|
| Common shares | 172,745,810 | Oct 30, 2026 |
Share count over time
| Count | Shares |
|---|---|
| Oct 30, 2026 | 172,745,810 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Eli Casdin Other companies: GeneDx Holdings Corp. (Board Member · Since at least Apr 27, 2022); Standard BioTools Inc. (Director · Since at least Apr 4, 2022); 2Seventy Bio Inc (Director · Mar 20, 2024 – May 13, 2025 · Past); EQRx Inc (Director · Sep 30, 2022 – Sep 30, 2022 · Past); Tenaya Therapeutics, Inc. (Director · Jun 10, 2022 – Nov 17, 2022 · Past); Century Therapeutics, Inc. (Director · Jun 9, 2022 – Jun 9, 2022 · Past) | Director · Jun 8, 2022 – Jun 8, 2022 · Past |
| Karen McGinnis Other companies: iRhythm Holdings, Inc. (Director · Since at least Jul 7, 2025); Alphatec Holdings, Inc. (Director · Since at least Jun 26, 2019); Sonendo, Inc. (Director · Oct 28, 2021 – Jun 16, 2023 · Past); Illumina, Inc. (VP, Chief Accounting Officer · Nov 14, 2017 – Feb 18, 2021 · Past); Cymer Inc (VP, Corporate Controller & CAO · Nov 30, 2009 – May 30, 2013 · Past); Insight Enterprises, Inc. (Chief Accounting Officer · Jan 19, 2006 – Feb 20, 2009 · Past) | Director · Since at least Jul 21, 2021 |
| Ivana Magovčević-Liebisch Other companies: Quanterix Corporation (Director · Since at least Oct 2, 2024); Acrivon Therapeutics, Inc. (Director · Since at least Feb 8, 2024); Vigil Neuroscience Inc (President and CEO, Director · Since at least Jan 6, 2022); Spyre Therapeutics, Inc. (Director · Jun 8, 2021 – Jun 22, 2023 · Past) | Director · Jul 21, 2021 – Jun 8, 2022 · Past |
| Daniel Rabinovitsj Other companies: ARRIS International Limited (PRESIDENT, ENTERPRISE NETWORKS · Dec 1, 2017 – Mar 30, 2018 · Past); QuickLogic Corporation (Director · May 14, 2016 – Jul 15, 2022 · Past); Ruckus Wireless Inc (Chief Operating Officer · Apr 5, 2016 – May 27, 2016 · Past) | Vice President, Meta · Since at least Nov 1, 2022 |
| Mary Szela Other companies: Averin Capital Acquisition Corp. (Director · Since at least Feb 18, 2026); Kura Oncology, Inc. (Director · Since at least Jun 5, 2025); TriSalus Life Sciences, Inc. (CEO and President, Director · Since at least Dec 31, 2024) | President, TriSalus Life Sciences · Since at least Jul 7, 2025 |
| Andreas Busch Other companies: Cyclerion Therapeutics, Inc. (Chief Scientific Officer · Apr 29, 2019 – Jan 20, 2022 · Past) | Chief Innovation Officer · Since at least Mar 17, 2022 |
| Joseph Sirosh Other companies: Compass, Inc. (Chief Technology Officer · Mar 31, 2021 – Aug 17, 2022 · Past) | Director · Since at least Jan 7, 2022 |
| Menelas Pangalos Other companies: Biogen Inc. (Director · Since at least Jan 1, 2025) | Director · Since at least Jan 1, 2024 |
| Alexander Khan | CVP, Finance & Investor Relations · Since at least Oct 27, 2026 |
| Alex KhanVP | Finance & Investor Relations · Since at least Dec 11, 2025 |
All 30 people
| Person | Seat |
|---|---|
| Amrit Nagpal | Director · Jul 21, 2021 – Jun 12, 2024 · Past |
| Andreas Pihl | Chief Operating Officer · Jul 21, 2021 – Jul 26, 2021 · Past |
| Christine Lemke | SVP, Portfolio and Growth Strategy · Since at least Nov 5, 2026 |
| ContactAlex KhanVP | Finance & Investor Relations · Since at least Dec 16, 2025 |
| Douglas Ganini da Silva | VP, Biologics Discovery & Research · Since at least Nov 5, 2026 |
| Frans van Houten | Director · Since at least Jun 2, 2023 |
| Gerry Muhle | Chief Commercial Officer · Since at least Nov 12, 2026 |
| Jeanne Schreuder | SVP, People & Experience · Since at least Nov 5, 2026 |
| Matthew Weinstock | Chief Technology Officer · Jul 21, 2021 – Feb 21, 2022 · Past |
| Mene Pangalos | Since at least Dec 12, 2024 |
| Michael Mangone | VP, Business Development · Since at least Nov 5, 2026 |
| Moetaz Albizem | SVP, Clinical Operations · Since at least Nov 5, 2026 |
| Ransi Somaratne | Chief Medical Officer · Since at least Mar 3, 2026 |
| Sarah Korman | Chief Legal Officer · Jul 21, 2021 – Mar 1, 2023 · Past |
| Sean McClain | Founder, CEO & Director · Since at least May 7, 2026 |
| Shelby Walker | Chief Legal Officer · Since at least Mar 2, 2026 |
| Todd Bedrick | SVP, Chief Accounting Officer · Since at least Jul 21, 2021 |
| Wen Sha | Chief of Staff · Since at least Nov 5, 2026 |
| Zachariah Jonasson | CFO / CBO · Since at least Jul 21, 2021 |
| Zach Jonasson | Chief Financial Officer & Chief Business Officer · Since at least Dec 12, 2024 |
Log in to ask 6ix AI your own questions about Absci Corporation.